Medical Pharmacology Chapter 36:  Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

Previous Page

Page Forward

Section Table of Contents

Site Table of Contents

References

  1. Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  2. Fauci AS Lane HC Chapter 226, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Kasper DL Fauci AS Hauser SL Longo DL Jameson JL Loscalzo J, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015 (on-line edition)

  3. Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012.

  4. Woster PM Chapter 43:  Antiviral Agents and Protease Inhibitors in Foye's Principles of Medicinal Chemistry 6e, Lemke, TL Williams DA, eds; Roche VG Zito SW, asst eds) Wolters Kluwer|Lippincott Williams & Wilkins 1214, 2008.

  5. HIV Overview:  The HIV Life Cycle, Education Materials, AIDSinfo, NIH http://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle

  6. Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version.

  7. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition.

  8. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014, https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf

  9. AIDSinfo:  Guidelines for the Use of Antriretroviral Agents in HIV-1-Infected Adults and Adolescents https://aidsinfo.nih.gov/guidelines (2015)

  10. NNRTI Resistance Notes (Stanford University, HIV Drug Resistance Database), March 2, 2014 http://hivdb.stanford.edu/DR/NNRTIResiNote.html

  11. Mackie N Chapter 2  Resistance to non-nucleoside reverse transcriptase inhibitors in Antiretroviral Resistance in Clinical Practice, Geretti AM, ED) London, 2006 http://www.ncbi.nlm.nih.gov/books/NBK2249/

  12. Gatanaga H Hachiya A Kimura S Oka S Mutations other than 103N in human immunnodeficiency virus type 1 reverse transcriptase (R) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.  Virology 344(2) 354-362 20 January 2006. http://www.sciencedirect.com/science/article/pii/S0042682205005660

  13. DNA Codon Table https://en.wikipedia.org/wiki/DNA_codon_table

  14. Haas DW Ribaudo HJ Kim RB Tierney C Wilkinson GR Gulick RM Clifford DB Hulgan T Marzolini C Acosta EP Pharmacogenetics of efavirenz and central nervous sustem side effects:  an Adult AIDS Clinical Trials Group study. AIDS 18(18):  2391-2400, December 3, 2004 http://www.ncbi.nlm.nih.gov/pubmed/15622315

  15. Weiss M Weiner J Carey M Shaliba E Efavirenz:  A non-nucleoside reverse transcriptase inhibitor https://www.youtube.com/watch?v=GKuXxn1gqkY

  16. AIDSinfo Recommendations for Use of Antiretroviral Drugs in Pregnana HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Updated March 28, 2014) https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_449.pdf

  17. Dermatology and Anti-retroviral Therapy:  Efavirenz http://hivpv.org/Home/SideEffects/Dermatology.aspx

  18. Wood BR NNRTI Resistance https://www.youtube.com/watch?v=mcHWUMvYubs

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.